Research programme: tuberculosis therapies - GlaxoSmithKline/Global Alliance for TB Drug Development

Drug Profile

Research programme: tuberculosis therapies - GlaxoSmithKline/Global Alliance for TB Drug Development

Latest Information Update: 21 Apr 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline; Global Alliance for TB Drug Development
  • Class
  • Mechanism of Action Acyltransferase inhibitors; DNA gyrase inhibitors; Peptide deformylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Research Tuberculosis

Most Recent Events

  • 25 Jan 2008 GlaxoSmithKline and the Global Alliance for TB Drug Development extend their collaboration for a further three years
  • 25 Jan 2008 Early research is ongoing in Spain
  • 21 Mar 2005 GlaxoSmithKline and the Global Alliance for TB Drug Development have entered into an alliance to co-develop novel tuberculosis therapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top